El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

731022.pdf (1.5 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-06-22

Llicència de publicació

cc-by (c) Espinosa, Gerard et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/201567

Persistent antiphospholipid antibodies are not associated with worse clinical outcomes in a prospective cohort of hospitalised patients with SARS-CoV-2 infection.

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fimmu.2022.911979

Resum

Objective: Patients with COVID-19 presented with an elevated prevalence of antiphospholipid antibodies (aPL) but the relationship with thrombosis is controversial. We analysed the persistence of aPL and their association with the clinical outcomes during hospitalisation in a cohort of COVID-19 patients. Patients and methods: We conducted a prospective study including consecutive hospitalised patients with COVID-19 from Hospital Clínic of Barcelona between March 28th and April 22nd, 2020. Clinical outcomes during hospitalisation were thrombosis, intensive care unit (ICU) admission, and severe ventilatory failure. We determined both criteria and non-criteria aPL. Of note, in those patients with a positive result in the first determination, a second sample separated by at least 12 weeks was drawn to test the persistence of aPL. Results: One hundred and fifty-eight patients (59.5% men) with a mean age of 61.4 ± 14.9 years old were included. Thrombosis was present in 28 (17.7%) patients, severe respiratory failure in 47 (30.5%), and 30 (18.9%) patients were admitted to ICU. Sixteen (28.6%) patients were positive for the criteria aPL at both determinations and only two (3.6%) of them suffered from thrombosis during hospitalisations (both had aCL IgG). However, they presented with low titers of aCL. Of note, aPL were not related to thrombosis, ICU admission or severe respiratory failure. Conclusion: Although aPL were prevalent in our cohort of hospitalised COVID-19 patients and they were persistent in half of tested patients, most determinations were at low titers and they were not related to worse clinical outcomes.

Matèries

COVID-19, SARS-CoV-2, Malalties autoimmunitàries, Síndrome antifosfolipídica, Diagnòstic, Trombosi, Insuficiència respiratòria

Matèries (anglès)

COVID-19, SARS-CoV-2, Autoimmune diseases, Antiphospholipid syndrome, Diagnosis, Thrombosis, Respiratory insufficiency

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ESPINOSA GARRIGA, Gerard, ZAMORA MARTÍNEZ, Carles, PÉREZ ISIDRO, Albert, NETO, Daniela, BRAVO GALLEGO, Luz yadira, PRIETO GONZÁLEZ, Sergio, VIÑAS, Odette, MORENO CASTAÑO, Ana belen, RUIZ ORTIZ, Estíbaliz, CERVERA I SEGURA, Ricard, The COVAPS-CLINIC Study Group Investigators. Persistent antiphospholipid antibodies are not associated with worse clinical outcomes in a prospective cohort of hospitalised patients with SARS-CoV-2 infection.. _Frontiers in Immunology_. 2022. Vol. 13, núm. 911979. [consulta: 23 de desembre de 2025]. ISSN: 1664-3224. [Disponible a: https://hdl.handle.net/2445/201567]

Exportar metadades

JSON - METS

Compartir registre